Abstracts Archive - Page 1300 of 2425 - ACR Meeting Abstracts

Abstract Number: 1417 • 2017 ACR/ARHP Annual Meeting
Mitophagy Defect in Fibroblast-like Synoviocytes of Rheumatoid Arthritis Is Improved By Pyruvate Treatment
Jeong Yeon Kim^1,2, ShinEui Kang^3,4, Hyun Jung Yoo^1,5, Ji Soo Park^1,2, Sehui Shon^1,2, Eun Young Lee², Eun Bong Lee⁵ and Yeong Wook Song^1,6, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea., Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea., Seoul, Korea, Republic of (South), ³Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea., seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea., seoul, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁶Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South)
Background/Purpose: Fibroblast-like synoviocytes (FLS) in the synovial intimal lining produce pro-inflammatory cytokines resulting in increase of joint inflammation. Recent studies about the cellular metabolism in…
Abstract Number: 1418 • 2017 ACR/ARHP Annual Meeting
The Value of Adalimumab Trough Levels and Clinical Assessments in Predicting Clinical Response in Patients with Established Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Josef S. Smolen¹, Nael Mostafa², Xin Huang², Peter Noertersheuser³, Ben Klünder³, Kun Chen², Jasmina Kalabic³, Iain Sainsbury², Ruud Oerlemans⁴, Stefan Florentinus⁴ and Gerd R. Burmester⁵, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁴AbbVie, Nederland, Hoofddorp, Netherlands, ⁵Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany
Background/Purpose: Low trough levels of the tumor necrosis factor inhibitor, adalimumab (ADL), and anti-ADL antibodies (AAA) were reported to be correlated with lack of response…
Abstract Number: 1419 • 2017 ACR/ARHP Annual Meeting
Characteristics of Patients with Early Rheumatoid Arthritis Who Have a Delayed Response to Treatment with Methotrexate in Monotherapy or in Combination with Adalimumab
Josef S. Smolen¹, Xianwei Bu², Xin Wang², Jessica L. Suboticki³ and Arthur Kavanaugh⁴, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., Mettawa, IL, ⁴Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), treat-to-target recommendations call for adjustment of treatment if a target is not met within 3-6 months (mths)…
Abstract Number: 1420 • 2017 ACR/ARHP Annual Meeting
The Ability of Patients with Early Rheumatoid Arthritis to Taper Low-Dose Glucocorticoids on Methotrexate Monotherapy and in Combination with Adalimumab
Josef S. Smolen¹, Prashanth Sunkureddi², Jaclyn K. Anderson³, Jenny Griffith³, Dingfeng Jiang³, Kun Chen³, Jessica L. Suboticki⁴ and Arthur Kavanaugh⁵, ¹Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Clear Lake Rheumatology, Nassau Bay, TX, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., Mettawa, IL, ⁵Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Low dose glucocorticoids (GCs) are recommended in combination with ≥1 synthetic DMARDs as part of the initial treatment strategy in rheumatoid arthritis (RA), with…
Abstract Number: 1421 • 2017 ACR/ARHP Annual Meeting
Tofacitinib Monotherapy Improves Arterial Stiffness in Conventional Dmards Active Rheumatoid Arthritis Patients. a Cohort Study
Kensuke Kume¹, Kanzo Amano², Susumu Yamada¹, Toshikatsu Kanazawa³ and Kazuhiko Hatta⁴, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²rheumatology., hiroshima clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴Rheumatology, Hatta Clinic, Kure, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk. We should have strategies for primary cardiovascular　prevention in RA. We reported Tofacitinib(Tofa) plus…
Abstract Number: 1422 • 2017 ACR/ARHP Annual Meeting
Impact of Adalimumab on Prednisone Use in Patients with Rheumatoid Arthritis in a Real World Setting – Results from the Corrona Registry
Dimitrios A. Pappas¹, Chitra Karki¹, Heather J. Litman¹, Taylor Blachley¹, Jessica L. Suboticki², Jenny Griffith³ and Joel Kremer⁴, ¹Corrona, LLC, Southborough, MA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., North Chicago, IL, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Steroids are used to reduce inflammation and pain among rheumatoid arthritis (RA) patients, but they can cause harmful side effects, and in some patients,…
Abstract Number: 1423 • 2017 ACR/ARHP Annual Meeting
Patterns of Prednisone Use in US Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine Clinical Practice
Dimitrios A. Pappas¹, Carol J. Etzel², Jennie Best³, Steve Zlotnick³, Taylor Blachley², Gioia Persuitte² and Joel Kremer⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: There are limited data regarding the impact of tocilizumab (TCZ) treatment on prednisone use in patients with rheumatoid arthritis (RA). The objective of this…
Abstract Number: 1424 • 2017 ACR/ARHP Annual Meeting
Impact of Glucocorticoid Therapy on the Efficacy of SC Abatacept or Adalimumab in RA Patients with Inadequate Response to MTX: A Post Hoc Analysis of Data from a Head-to-Head Trial
Yannick Degboé^1,2, Michael Schiff³, Michael Weinblatt⁴, Roy Fleischmann⁵, HA Ahmad⁶ and Arnaud Constantin^2,7, ¹Toulouse University Hospital, Toulouse, France, ²Université Paul Sabatier, Toulouse, France, ³University of Colorado, Denver, CO, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Purpan University Hospital, Toulouse, France
Background/Purpose: In patients with RA, low-dose glucocorticoids (GCs) have been shown to increase clinical, functional and radiographic efficacy when combined with conventional synthetic DMARDs;1 however,…
Abstract Number: 1425 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Patients with Rheumatoid Arthritis Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry
Philip J Mease¹, Neil Accortt², Mei Liu³, Sabrina Rebello³, Mahdi Gharaibeh² and David Collier², ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Amgen Inc., Thousand Oaks, CA, ³Corrona, LLC, Southborough, MA
Background/Purpose: Many treatment options are currently available to patients with rheumatoid arthritis (RA), including tumor necrosis factor inhibitors (TNFi’s). While combination therapy of TNFi’s or…
Abstract Number: 1426 • 2017 ACR/ARHP Annual Meeting
Higher Levels of Interleukin-6 As Well As Soluble Interleukin-6 Receptor Leads to Worse Clinical and Radiographic Prognosis in Rheumatoid Arthritis Patients Treated with Tocilizumab
Naoshi Nishina, Yuko Kaneko, Keiko Yoshimoto and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: We have already reported that baseline levels of soluble interluekin-6 receptor (sIL-6R), target of tocilizumab, predicted response to tocilizumab treatment in rheumatoid arthritis (RA)…
Abstract Number: 1427 • 2017 ACR/ARHP Annual Meeting
Monitoring of Absolute Lymphocyte Count in Patients with Rheumatoid Arthritis Treated with Tofacitinib
Gerd R. Burmester¹, Zoltan Szekanecz², Pinaki Biswas³, Sriram Krishnaswami⁴, Christopher F Mojcik³, Hernan Valdez³, Jamie Geier³ and Sander Strengholt⁵, ¹Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ²University of Debrecen Faculty of Medicine, Debrecen, Hungary, ³Pfizer Inc, New York, NY, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Capelle aan den IJssel, Netherlands
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Lymphopenia is a frequent feature of RA,1 and RA medications may also…
Abstract Number: 1428 • 2017 ACR/ARHP Annual Meeting
Discovery and Characterization of JNJ-61178104, a Bispecific Antibody Against Human Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL)-17A
Fang Shen¹, Jennifer F. Nemeth², Brian Jones¹, Ann Cai¹, Shannon Hitchcock³, Thai Dinh², Ravi Malaviya¹ and Tatiana Ort¹, ¹Immunology, Janssen R&D, Spring House, PA, ²Janssen Biotech, Janssen R&D, Spring House, PA, ³Immunology, Janssen R&D, Springhouse, PA
Background/Purpose: Tumor necrosis factor alpha (TNFa) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including Rheumatoid Arthritis (RA) and…
Abstract Number: 1429 • 2017 ACR/ARHP Annual Meeting
Incidence Rates of Adverse Events with Death As an Outcome during Abatacept Treatment in RA: Results from an Integrated Data Analysis from 16 Clinical Trials
D Fleming¹, TA Simon¹, A Torbeyns², U Meier-Kriesche¹ and A Johnsen¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Braine l’Alleud, Belgium
Background/Purpose: Patients with RA have a 1.5–2-fold increased risk of mortality compared with the general population. The association between mortality rates and different RA treatments…
Abstract Number: 1430 • 2017 ACR/ARHP Annual Meeting
Switching from Synthetic to Biologic Dmards – Is There an Insufficient Use of Methotrexate?
Lisa Baganz¹, Adrian Richter¹, Yvette Meißner², Matthias Schneider³, Anke Liebhaber⁴, Ilka Schwarze⁵, Anja Strangfeld⁶ and Angela Zink⁷, ¹German Rheumatism Research Center, Berlin, Germany, ²Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, ⁴Rheumatologist, Halle, Germany, Halle, Germany, ⁵Rheumatologist, Leipzig, Germany, Leipzig, Germany, ⁶Epidemiology, German Rheumatism Research Center, Berlin, Germany, ⁷German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: A recent US-study suggests considerable underuse of MTX and too early switches to biologic (b)DMARDs1 before using a high MTX dose or changing the…
Abstract Number: 1431 • 2017 ACR/ARHP Annual Meeting
Serum Trough Levels of Adalimumab Inversely Correlate with Disease Activity in Patients with Inflammatory Arthritis
Daman Langguth¹, Peter Wong², Alison Bowling³, Hanish Bagga⁴, Di Freeman⁴ and emma ford⁵, ¹Immunology, Sullivan Nicolaides Pathology, Brisbane, Australia, ²Mid-North Coast Arthritis Clinic and University of New South Wales Rural Clinical School, Coffs Harbour, Australia, ³School of health and human sciences, Southern Cross University, Coffs Harbour, Australia, ⁴Mid-North Coast Arthritis Clinic, Coffs Harbour, Australia, ⁵Mid North Coast Arthritis Clinic, Coffs Harboyr, Australia
Background/Purpose: Targeted blockade of TNF has been a major advance in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].